Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
89
Views
118
CrossRef citations to date
0
Altmetric
Review

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update

Len Neckers National Cancer Institute, Urologic Oncology Branch, 9610 Medical Ctr., Suite 300, Rockville, MD 20850, USA. [email protected]
&
Katharine Neckers New England School of Law, Boston, MA 02116, USA
Pages 137-149 | Published online: 22 Apr 2005

Bibliography

  • STOLER DL, CHEN N, BASIK M et al: The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Nail. Acad. Sci. USA (1999) 96(20 :15121–15126.
  • HAHN WC, WEINBERG RA: Modelling the molecular circuitry of cancer. Nat. Rev. Cancer (2002) 2(5):331–341.
  • LA ROSEE P, O'DWYER ME, DRUKER BJ: Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia (2002) 16(7):1213–1219.
  • KITANO H: Cancer robustness: tumourtactics. Nature (2003) 426(6963):125.
  • HANAHAN D, EINBERG RA: The hallmarks of cancer. Cell (2000) 100(1):57–70.
  • CHIOSIS G, VILENCHIK M, KIM J, SOLIT D: Hsp90: the vulnerable chaperone. Drug Discov. Today (2004) 9(20):881–888.
  • WORKMAN P: Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. (2004) 206(2):149–157.
  • BAGATELL R, WHITESELL L: Altered Hsp90 function in cancer: a unique therapeutic opportunity. MoL Cancer Ther. (2004) 3(8):1021–1030.
  • ZHANG, BURROWS F: Targeting multiple signal transduction pathways through inhibition of Hsp90.1 Md. Med. (2004) 82(8):488–499.
  • GOETZ MP, TOFT DO, AMES MM, ERLICHMAN C: The Hsp90 chaperone complex as a novel target for cancer therapy. Ann. Oncol (2003) 14(8):1169–1176.
  • ISAACS JS, ISAACS JS, XU W, NECKERS L: Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3(3):213–217.
  • RUTHERFORD SL, LINDQUIST S: Hsp90 as a capacitor for morphological evolution. Nature (1998) 396(6709):336–342.
  • QUEITSCH C, SANGSTER TA, LINDQUIST S: Hsp90 as a capacitor of phenotypic variation. Nature (2002) 417(6889):618–624.
  • NECKERS L, IVY SP: Heat shock protein 90. Curr. Opin. Oncol (2003) 15: 419–424.
  • MUNSTER PN et al.: Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol (2001) 20:Abstract 326.
  • BANERJI U et al.: A pharmacokinetically (Pk) - pharmacodynamically (Pd) driven Phase I trial of the Hsp90 molecular chaperone inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG). Proceedings from the 93rd Annual Meeting of the American Association for Cancer Research. (2002) 43:Abstract 1352.
  • AGNEW EB et al.: Clinical pharmacokinetics of 17-(allylamino)-17-demethoxygeldanamycin and the active metabolite 17-(amino)-17-demethoxygeldanamycin given as a one-hour infusion daily for 5 days. Proceedings from the 93rd Annual Meeting of the American Association for Cancer Research. (2002) 43:Abstract 1349.
  • IVY PS, SCHOENFELDT M: Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG. Oncology (Huntingt) (2004) 18(5):619–620.
  • MARCU MG, SCHULTE TW, NECKERS L: Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl Cancer Inst. (2000) 92(3):242–248.
  • MARCU MG, CHADLI A. BOUHOUCHE I, CATELLI M, NECKERS LM: The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. (2000) 275(47):37181–37186.
  • SOTI C, RACZ A, CSERMELY P: A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. j Biol. Chem. (2002) 277(9):7066–7075.
  • MARCU MG, NECKERS LM: The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function. Curr. Cancer Drug Targets (2003) 3(5):343–347.
  • YU X, GUO ZS, MARCU MG et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.1 Natl Cancer Inst. (2002) 94(7):504–513.
  • FUINO L, BALI P, WITTMANN S et al.: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. (2003) 2(10971–984.
  • NECKERS L, NECKERS K: Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin. Emerging Drugs (2002) 7:277–288.
  • SILIGARDI G et al.: Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem. (2004).
  • WEGELE H, MULLER L, BUCHNER J et al.: Hsp70 and Hsp90-a relay team for protein folding. Rev. PhysioL Biochem. Pharmacol (2004) 151:1–44.
  • PRODROMOU C, PEARL LH: Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets (2003) 3(5):301–323.
  • SILIGARDI G, PANARETOU B, MEYER P et al.: Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37.1 Biol. Chem. (2002) 277(23):20151–20159.
  • SCHEIBEL T, BUCHNER J: The Hsp90 complex-a super-chaperone machine as a novel drug target. Biochem. Pharmacol (1998) 56(61:675–682.
  • NECKERS L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. (2002) 8(4 Suppl.):555–561.
  • AN WG, SCHULTE TW, NECKERS LM et al.: The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. (2000) 11(7):355–360.
  • XU Y, SINGER MA, LINDQUIST S: Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc. Natl Acad. ScLUSA (1999) 96(1):109–114.
  • EISEMAN JL et al.: Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2 dimethylamino)ethyll amino] geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother. Pharmacol (2004).
  • CHIOSIS G, HUEZO H, ROSEN N, MIMNAUGH E, WHITESELL L, NECKERS L: 17AAG: Low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther. (2003) 2(2):123–129.
  • KAMAL A, THAO L, SENSINTAFFAR J et al.: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 425(6956):407–410.
  • VILENCHIK M, SOLIT D, BASSO A et al.: Targeting wide-range oncogenic transformation via PU24FC1, a specific inhibitor of tumor Hsp90. Chem. Biol. (2004) 11:787–797.
  • FUJIMOTO J, SHIOTA M, IWAHARA T et al.: Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc. Natl Acad. Sci. USA (1996) 93(9):4181–4186.
  • BONVINI P, GASTALDI T, FALINI B, ROSOLEN A: Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90- client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res. (2002) 62(5):1559–1566.
  • NAOE T, KIYOE H, YAMAMOTO Y et al.: FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother. Pharmacol. (2001) 48\(Suppl. 1):S27–S30.
  • MINAMI Y, KIYOI H, YAMAMOTO Y et al.: Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia (2002) 16(8):1535–1540.
  • SHIOTSU Y, NECKERS LM, WORTMAN I et al.: Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood (2000) 96(6):2284–2291.
  • DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2(5):561–566.
  • SAWYERS CL, HOCHHAUS A. FELDMAN E et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99(10):3530–3539.
  • SHAH NP, NICOLL JM, NAGAR B et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (5TI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117–125.
  • GORRE ME, ELLWOOD-YEN K, CHIOSIS G, ROSEN N, SAWYERS CL: BCR-ABL point mutants isolated from patients with 5TI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood (2002) 100:3041–3044.
  • NIMMANAPALLI R, O'BRYAN E, HUANG M et al: Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. (2002) 62(20):5761–5769.
  • FUMO G, AKIN C, METCALFE DD, NECKERS L: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood (2004) 103:1078–1084.
  • VANAJA DK, MITCHELL SH, TOFT DO, YOUNG CY: Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones (2002) 7:55–64.
  • GEORGET V TEROUANNE B, NICOLAS JC, SULTAN C: Mechanism of antiandrogen action: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry (2002) 41:11824–11831.
  • SOLIT D, ZHENG FF, DROBNJAK M et al: 17-allylamino-17-demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. (2002):986–993.
  • HARRIS AL: Hypoxia- a key regulatory factor in tumor growth. Nat. Rev. Cancer (2002) 2:38–47.
  • MAXWELL PH, WIESENER MS, CHANG GW et al.: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 399:271–275.
  • SEIZINGER BR, ROULEAU GA, OZELIUS LJ et al: Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature (1988) 332(6161):268–269.
  • GRADIN K, MCGUIRE J, WENGER RH et al: Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. MoL Cell. BioL (1996) 16(10):5221–5231.
  • HUR E, KIM HH, CHOI SM et al: Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-lalpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-1cDa heat-shock protein inhibitor radicicol. Mol. PharmacoL (2002) 62(5):975–982.
  • ISAACS JS, JUNG YJ, MIMNAUGH EG, MARTINEZ A, CUTTITTA F, NECKERS LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. BioL Chem. (2002) 277(33):29936–29944.
  • MABJEESH NJ, POST DE, WILLARD MT et al.: Geldanamycin induces degradation of hypoxia-inducible factor la protein via the proteasome pathway in prostate cancer cells. Cancer Res. (2002) 62:2478–2482.
  • ZAGZAG D, NOMURA M, FRIEDLANDER DR et al.: Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-lalpha) in glioma cell invasion. J. Cell. Physiol. (2003) 196(2):394–402.
  • DIAS S, SHMELKOV SV, LAM G, RAFII S: VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bc1-2 expression and apoptosis inhibition. Blood (2002) 99(7):2532–2540.
  • MAULIK G, KIJIMA T, MA PC et al: Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. (2002) 8(2):620–627.
  • PENNACCHIETTI S, MICHIELI P, GALLUZZO M et al: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 3(4):347–361.
  • TACCHINI L, DANSI P, MATTEUCCI E, DESIDERIO MA: Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis (2001) 22(9):1363–1371.
  • BOTTARO DP, LIOTTA LA: Out of air is not out of action. Nature (2003) 423:593–595.
  • MIMNAUGH EG, CHAVANY C, NECKERS L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. j BioL Chem. (1996) 271(37):22796–22801.
  • SCHNEIDER C, SEPP-LORENZINO L, NIMMESGERN E et al.: Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. NatL Acad. Sci. USA (1996) 93(25):14536–14541.
  • BASSO AD, SOLIT DB, CHIOSIS G, GIRT B, TSICHLIS P, ROSEN N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function./ BioL Chem. (2002) 277(42):39858–39866.
  • FRENCH BA, VAN LEEUWEN F, RILEY NE et al: Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. Exp. MoL PathoL (2001) 71(3):241–246.
  • WAELTER S, BOEDDRICH A. LURZ R et al.: Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. MoL Biol. Cell (2001) 12(5):1393–1407.
  • AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8(8):2505–2511.
  • EALLEMAIN G: [Update on. the proteasome inhibitor PS341]. Bull. Cancer (2002) 89(1):29–30.
  • MITSIADES N, MITSIADES CS, POULAKI V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. NatL Acad. Sci. USA (2002) 99(22):14374–14379.
  • MIMNAUGH EG, XU W, VOS M et al.: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol. Cancer Ther. (2004) 3(5):551–566.
  • BISHT KS, BRADBURY CM, MATTSON D et al.: Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. (2003) 63(24):8984–8995.
  • MACHIDA H, MATSUMOTO Y, SHIRAI M, KUBOTA N: Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int. J. Radiat. Biol. (2003) 79(12):973–980.
  • BECKER B, MULTHOFF G, FARKAS B et al.: Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp. DermatoL (2004) 13(1):27–32.
  • EUSTACE BK, SAKURAI T, STEWART JK et al.: Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. (2004) 6(6):507–514.
  • EUSTACE BK, JAY DG: Extracellular roles for the molecular chaperone, hsp90. Cell Cycle (2004) 3(9):1098–1100.
  • WRIGHT L, BARRIL X, DYMOCK B et al.: Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. (2004) 11(6):775–785.
  • SCHULTE TW, AKINAGA S, SOGA S et al.: Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones (1998) 3(2):100–108.
  • SHARMA SV, AGATSUMA T, NAKANO H: Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene (1998) 16(20):2639–2645.
  • CHIOSIS G, LUCAS B, HUEZO H, SOLIT D, BASSO A, ROSEN N: Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets (2003) 3(5):371–376.
  • MATTHEWS RC, RIGG G, HODGETTS S et al.: Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. (2003) 47(7):2208–2216.
  • MATTHEWS R, BURNIE J: Recombinantantibodies: a natural partner in combinatorial antifungal therapy. Vaccine (2004) 22:865–871.
  • KELLAND LR, SHARP SY, ROGERS PM, MYERS TG, WORKMAN P: DT-diaphorase expression and tumor cell sensitivity to 17-allylamino-17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.1 Natl. Cancer Inst. (1999) 91:1940–1949.
  • ALI A, BHARADWAJ S, O'CARROLL R, OVSENEK N: HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. MoL Cell. Biol. (1998) 18(9):4949–4960.
  • KIM HR, KANG HS, KIM HD: Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life (1999) 48(4):429–433.
  • XIAO N, CALLAWAY CW, LIPINSKI CA, HICKS SD, DEFRANCO DB: Geldanamycin provides posttreatment protection against glutamate- induced oxidative toxicity in a mouse hippocampal cell line. J. Neurochem. (1999) 72(1):95–101.
  • GUO Y, GUETTOUCHE T, FENNA M et al.: Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. 1 Biol. Chem. (2001) 276(49):45791–45799.
  • LU A, RAN R, PARMENTIER-BATTEUR S, NEE A, SHARP FR: Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. j Neurochem. (2002) 81(2):355–364.
  • BAGATELL R, PAINE-MURRIETA GD, TAYLOR CW et al.: Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin. Cancer Res. (2000) 6(8):3312–3318.
  • MIMNAUGH EG, WORLAND PJ, WHITESELL L, NECKERS LM: Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. j Biol. Chem. (1995) 270(48):28654–28659.
  • ZHAO YG, GILMORE R, LEONE G, COFFEY MC, WEBER B, LEE PW: Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein. J. Biol. Chem. (2001) 276(35):32822–32827.
  • SMITH-JONES PM, SOLIT DB, AKHURST T, AFROZE F, ROSEN N, LARSON SM: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat. Biotechnol. (2004) 22(6):701–706.

Website

  • http://www.picard.ch/DP/downloads/ Hsp9Ointeractors.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.